Logo

Regeneron and Sanofi Present Results of Dupixent (dupilumab) in P-III VOYAGE Study for Asthma at ATS 2021

Share this

Regeneron and Sanofi Present Results of Dupixent (dupilumab) in P-III VOYAGE Study for Asthma at ATS 2021

Shots:

  • The P-III VOYAGE trial involves assessing Dupixent (100/200mg- q2w- based on weight) + SOC asthma therapy in 408 children aged 6-11yrs. with uncontrolled mod. to-sev. asthma with evidence of type 2 inflammation
  • Results: improvement in asthma control @24wks. (1.34/ 1.33 vs 0.88/ 1.00); improvement in ACQ-7-IA; reduction in mean FeNO levels to below the threshold for type 2 inflammation; improvement in overall asthma symptom control
  • The safety and efficacy of Dupixent in the pediatric population have not been fully evaluated by any regulatory authority. The company is expecting the FDA’s decision in this population by Oct 21- 2021

  Ref: Regeneron | Image: Clinical Trials Arena

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions